SPTLC2

Across TCGA pan-cancer cohorts, SPTLC2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SPTLC2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SPTLC2 RNA is repressed in tumor relative to normal tissue. In most cancer types SPTLC2 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, LIHC, and BLCA are the cancer types where SPTLC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPTLC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	−0.572	<.001	9	view →
LIHC	Female	II,III,IV	+0.972	<.001	8	view →
BLCA	All	III,IV	+0.634	.011	7	view →
BRCA	All	All	+0.440	<.001	6	view →
CHOL	Male	All	+2.250	<.001	5	view →
STAD	Male	All	+0.765	.003	4	view →
KIRP	Female	II,III,IV	+0.758	.048	2	view →
PRAD	All	All	+0.367	.001	2	view →
COAD	Female	All	−0.442	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SPTLC2–KIRC

Open the KIRC breakdown →